Epilepsy

Active Ingredient: Valproic acid

Indication for Valproic acid

Population group: only adults (18 years old or older)

Treatment of generalised, partial or other epilepsy.

For this indication, competent medicine agencies globally authorize below treatments:

600-2,500 mg in 3 divided doses daily

Route of admnistration

Oral

Defined daily dose

600 - 2,500 mg

Dosage regimen

From 200 To 833.333 mg 3 time(s) per day every day

Detailed description

Dosage should start at 600 mg daily increasing by 200 mg at three-day intervals until control is achieved. This is generally within the dosage range 1,000–2,000 mg per day, i.e. 20–30 mg/kg/day body weight (to the nearest whole 50 mg sachet). Where adequate control is not achieved within this range the dose may be further increased to 2,500 mg per day.

10-25 mg/kg daily

Route of admnistration

Intravenous

Defined daily dose

10 - 25 mg per kg of body weight

Dosage regimen

From 10 To 25 mg per kg of body weight once every day

Detailed description

Valproate acid intravenous may be given by direct slow intravenous injection or by infusion using a separate intravenous line in normal saline, dextrose 5%, or dextrose saline.

Daily dosage requirements vary according to age and body weight.

To reconstitute, inject the solvent provided (4 ml) into the vial, allow to dissolve and extract the appropriate dose. Due to displacement of solvent by sodium valproate the concentration of reconstituted sodium valproate is 95 mg/ml.

Each vial of valproate acid intravenous is for single dose injection only. It should be reconstituted immediately prior to use and infusion solutions containing it used within 24 hours. Any unused portion should be discarded.

Valproate acid intravenous should not be administered via the same IV line as other IV additives. The intravenous solution is suitable for infusion by PVC, polyethylene or glass containers.

Patients already satisfactorily treated with valproate acid may be continued at their current dosage using continuous or repeated infusion. Other patients may be given a slow intravenous injection over 3–5 minutes, usually 400–800 mg depending on body weight (up to 10 mg/kg) followed by continuous or repeated infusion up to a maximum of 2,500 mg/day.

Valproate acid intravenous should be replaced by oral valproate acid therapy as soon as practicable.

10-60 mg/kg in 3 divided doses daily

Route of admnistration

Oral

Defined daily dose

10 - 60 mg per kg of body weight

Dosage regimen

From 3.333 To 20 mg per kg of body weight 3 time(s) per day every day

Active ingredient

Valproic acid

Valproic acid is anti-convulsant. The most likely mode of action for valproate is potentiation of the inhibitory action of gamma amino butyric acid (GABA) through an action on the further synthesis or further metabolism of GABA.

Read more about Valproic acid

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.